Prevalence of abnormal cervical cancer screening outcomes among screening-compliant women in the United States
Formal guidelines recommend routine cervical cancer screening using the Papanicolaou test alone, every 3 years, for women aged 21 –65 years; high-risk human papillomavirus testing alone or concurrent hr human papillomavirus and Papanicolaou test (co-testing), every 5 years, for women aged 30–65 years.1–3 Early detection of precursor lesions through routine screening is central to cervical cancer prevention.1 However, lit tle is known about the prevalence of abnormal screening outcomes by cervical cancer screening modality.
Conclusion: Sub-Saharan countries still have a long way to go in controlling the high burden of cervical cancer. Effective prevention methods exist, such as HPV vaccination and screening, but their affordability and implementation remain challenging for most of these countries. Despite that, there is still light on the horizon, as the cost of HPV vaccines has been steadily decreasing and most African countries are using the more cost-effective methods of cervical cancer screening. PMID: 31552125 [PubMed]
CONCLUSIONS: A small proportion of Latvian women are over-screened, whereas many women remain unscreened. The main contributing factor for this was their poor understanding of the roles that cervical screening and HPV vaccination play in preventing CC. PMID: 31545387 [PubMed - in process]
For its first few years on the market, the human papillomavirus (HPV) vaccine was approved only for young girls. Over time, the U.S. Food and Drug Administration (FDA) has broadened its approval to include boys, as well as adults up to age 45—allowing more people to get the cancer-preventing vaccine, but also breeding confusion about who should get vaccinated and when. On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) released new recommendations, based on guidance from the Advisory Committee on Immunization Practices, that should clear up some of that confusion. The CDC reaffirmed that its prior...
CONCLUSIONS: The higher frequency of HR-HPV than the LR-HPV withidentification of 4 mixed cases indicates that our women are at risk of developing cervical cancer. Detection of HR-HPVin NILM and ASC-US smears with restriction of some strains to these 2 categories highlights the great value of HPVgenotyping as a surrogate test to pick up unscreened women at risk of developing cervical malignancy particularlywhen a proper screening program is absent. PMID: 31350966 [PubMed - in process]
Authors: Song T, Seong SJ, Lee SK, Kim BR, Ju W, Kim KH, Nam K, Sim JC, Kim TJ Abstract The purpose of this study was to develop an ideal cervical cancer screening model to reduce false-negative errors in Korea where there is a high prevalence of cervical cancer. We conducted a cross-sectional study including 33,531 women who underwent routine cervical cancer screening in Korea. Colposcopic examinations were performed after abnormal results on their screening tests. Diagnostic capacities including sensitivity, specificity, and false-negative rate of each screening scenario were analysed at the CIN1 or worse (CIN1+)...
CONCLUSIONS: Korean women were more likely to report satisfaction with alternative modalities (self-sampling and urine sampling) for CCS in comparison to the Pap test. This suggests that self-collected modalities may help with improving CCS uptake rates by eliminating burden related with the Pap test. However, further studies for test accuracy and cost-effective analysis of the alternative modalities should be conducted in order to apply CCS. PMID: 31328458 [PubMed - in process]
CONCLUSION: There is a lack of knowledge and misinformation regarding cervical cancer, Pap smears, HPV, and HPV association with cervical cancer. These data can be used as a basis to formulate effective population awareness programs. PMID: 31219489 [PubMed - in process]
CONCLUSIONS: These findings highlight the need for educational campaigns regarding HPV infection, its potential as a cervical cancer agent and the forms of prevention available.RESUMO OBJETIVO: O papilomav írus humano (HPV) é o vírus sexualmente transmissível mais prevalente no mundo, estando a infecção por este agente associada a um aumento do risco do câncer de colo uterino. A abordagem mais eficaz para o controle desse tipo de câncer continua sendo a triagem por meio do exame preventivo (Pa panicolaou). Este estudo analisa o conhecimento de estudantes universit&aacut...
In conclusion, the HPV prevalence and genotype distribution in our study are similar to those reported in the world, but higher than previous studies in our country. These results may be due to our methodology and hospital based nature of our study group. We conclude that only smear or HR-HPV testing are not sufficient as a single pronged screening test, and that the participation of other genotypes of HPV in screening increases the sensitivity. PMID: 31130121 [PubMed - in process]
Conclusions: There is a need, therefore, to create awareness programs for cervical cancer, its causes and risk factors, as well as its preventive measures for women in the southern region of Saudi Arabia. PMID: 31030492 [PubMed - in process]